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Penicillin and related beta-lactams comprise one of
our oldest and most widely used antibiotic therapies.
These drugs have long been known to target en-
zymes called penicillin-binding proteins (PBPs) that
build the bacterial cell wall. Investigating the down-
stream consequences of target inhibition and how
they contribute to the lethal action of these important
drugs, we demonstrate that beta-lactams do more
than just inhibit the PBPs as is commonly believed.
Rather, they induce a toxic malfunctioning of their
target biosynthetic machinery involving a futile cycle
of cell wall synthesis and degradation, thereby de-
pleting cellular resources and bolstering their killing
activity. Characterization of this mode of action ad-
ditionally revealed a quality control function for en-
zymes that cleave bonds in the cell wall matrix. The
results thus provide insight into the mechanism of
cell wall assembly and suggest how best to interfere
with the process for future antibiotic development.INTRODUCTION
Penicillin and related beta-lactam drugs are one of our oldest
and most widely used antibiotic classes. They have long been
known to interfere with bacterial cell wall assembly as part of
their mode of action (Park and Strominger, 1957). The cell wall
is an essential polysaccharide structure that surrounds most
bacterial cells and protects their cytoplasmic membrane from
osmotic rupture. It is built from the polymer peptidoglycan
(PG), which consists of glycan chains with attached peptides
used to crosslink adjacent glycans to form a matrix structure
(Figure 1A).
Beta-lactams disrupt PG biogenesis by inactivating enzymes
called penicillin-binding proteins (PBPs) (Tipper and Strominger,
1965). Bacteria encode a variety of PBPs that participate in PG
assembly (Sauvage et al., 2008). The high-molecular-weight
PBPs are the major PG synthases. They are subdivided into
class A (aPBPs) and class B (bPBPs) enzymes (Figure 1B).
aPBPs are bifunctional and possess both glycosyltransferase
(GT) activity for polymerizing the glycan strands and transpepti-1300 Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc.dase (TP) activity for crosslinking them. bPBPs, on the other
hand, are only known to possess TP activity. The primary target
of beta-lactams is the TP active site of the synthetic PBPs, which
is covalently modified by the drug. In addition to the PG syn-
thases, beta-lactams also inhibit the low-molecular-weight
PBPs. These factors belong to a large and diverse family of en-
zymes that cleave bonds in the PG matrix. Such enzymes, often
referred to as PG hydrolases, are typically nonessential, but have
been found to play important roles in morphogenesis (Uehara
and Bernhardt, 2011).
The lethal activity of beta-lactams is thought to stem princi-
pally from the loss of wall integrity accompanied by cell lysis
(Park and Strominger, 1957). According to the most widely
accepted model, cell wall damage following beta-lactam treat-
ment results from a drug-induced imbalance between the activ-
ities of cell wall synthases and hydrolases (Schwarz et al., 1969;
Tomasz and Waks, 1975; Tomasz et al., 1970). This view is sup-
ported by the observation that PG hydrolase inactivation can
prevent or delay beta-lactam-induced cell lysis (Chung et al.,
2009; Heidrich et al., 2002; Tomasz, 1979; Tomasz and Waks,
1975; Tomasz et al., 1970; Uehara et al., 2009). However,
surprisingly little mechanistic insight underlies this general
framework for drug action. It remains largely unclear which PG
hydrolases disrupt the wall following drug treatment andwhether
these autolysins are ‘‘induced’’ to damage the wall or are simply
carrying out their normal physiological function in the absence of
TP activity. Clues suggesting a more complex mode of action for
beta-lactams than simple TP inhibition have also been reported.
Surprisingly, in Streptococcus pneumoniaemutants blocked for
cell lysis, beta-lactam treatment still promoted cell death with ki-
netics similar to lysing cells (Moreillon et al., 1990). Additionally,
in Escherichia coli, beta-lactams were unexpectedly shown to
cause a depletion of lipid-linked cell wall precursors prior to
cell lysis (Kohlrausch and Ho¨ltje, 1991).
The lysis-independent effects of beta-lactams indicate that
much remains to be learned about the events following TP inhi-
bition and how they contribute to the killing activity of this vital
class of antibiotics. These events have been difficult to elucidate
because the effect of drug treatment on cell growth and mor-
phology varies depending on the organism studied and on the
number of different PBPs inhibited by the beta-lactam derivative
used (Spratt, 1975). We overcame this challenge by studying the
activity of mecillinam, a beta-lactam specific for a single essen-
tial PBP in the model gram-negative bacterium Escherichia coli
Figure 1. Peptidoglycan Structure and the
Machines that Synthesize It
(A) The PG matrix consists of glycan chains with
the repeating unit of N-acetylmuramic acid (Mur-
NAc, M) and N-acetylglucosamine (GlcNAc, G).
Attached to the MurNAc sugars are peptides
(colored circles) used to form crosslinks between
adjacent glycans.
(B) Domain structure of the PG synthases. Both
classes of PBPs have a single transmembrane
domain with a large catalytic domain in the peri-
plasm.
(C and D) Schematics highlighting the components
of the two main PG synthetic systems in rod-sha-
ped bacteria. Both systems require a dedicated
bPBP (PBP2 or PBP3) and a SEDS (shape/elon-
gation/division/sporulation) family protein (RodA or
FtsW) for proper function. See text for details.(Spratt, 1975). Our analysis revealed that, beyond simply inhibit-
ing the TP activity of PBPs, mecillinam and other beta-lactams
stimulate a deleterious futile cycle of cell wall synthesis and
degradation by their target machineries that contributes to their
lethal activity. Additional genetic analysis identified the enzyme
responsible for beta-lactam-stimulated degradation of nascent
PG. Characterization of the in vivo activity of this factor suggests
a novel ‘‘quality control’’ function for cell wall cleaving enzymes
in PG biogenesis. Our findings thus provide new insight into
the cell wall assembly process in addition to uncovering an
important mechanism by which beta-lactam antibiotics induce
cell death.
RESULTS
Rationale
Like many rod-shaped bacteria, E. coli grows using two different
PG biogenesis systems (Typas et al., 2012) (Figures 1C and 1D).
The actin-like MreB protein and its partners constitute the Rod
system, which catalyzes the insertion of new PG material along
the cell body to promote cell elongation (Typas et al., 2012) (Fig-
ure 1C). The tubulin-like FtsZ protein, on the other hand, orga-
nizes the divisome to synthesize PG for the new daughter cell
poles (de Boer, 2010) (Figure 1D). Each of these machineries
requires an essential bPBP for their activity: PBP2 for the Rod
system and PBP3 for the divisome (Typas et al., 2012) (Figures
1B–D). Proper PG biogenesis by these systems in E. coli is
also thought to require the aPBPs, PBP1a and PBP1b, to pro-
mote glycan chain polymerization and crosslinking (Typas
et al., 2012) (Figures 1B–1D).Cell 159, 1300–1311, DRod system function is normally
required for viability (Bendezu´ and de
Boer, 2008; Kruse et al., 2005). Inactiva-
tion of any of the essential components
(MreB, MreC, MreD, PBP2, or RodA),
causes cells to form spheres that fail to
divide and eventually lyse. This lethal
phenotype can be suppressed by over-
production of the division protein FtsZ,with the Rod- FtsZup cells growing and dividing as small spheres
(Bendezu´ and de Boer, 2008; Kruse et al., 2005; Vinella et al.,
1992). However, the mechanism by which increased FtsZ con-
centration suppresses the lethality of Rod system inactivation
is not clear. In addition to genetic inactivation, Rod system func-
tion can also be blocked with the small molecules A22 (Gitai
et al., 2005) or mecillinam (Spratt, 1975) (Figure 2A). A22 inacti-
vates MreB (Gitai et al., 2005), and mecillinam is a beta-lactam
that is specific for the TP active site of PBP2 (Spratt, 1975).
Because PBP2 can be rendered nonessential by the overpro-
duction of FtsZ (Vinella et al., 1993) (Figure 2B), we reasoned
that studies of mecillinam presented a unique opportunity to
study the consequences of PBP inhibition by beta-lactams un-
der conditions where the target is not required for growth.
Mecillinam Induces a Lethal Malfunctioning of the
Rod System
The lethal effects of inactivating MreB with A22 are suppressed
by the low-copy vector pTB63, from which the ftsQAZ operon is
expressed via its native promoters (a condition we will hence-
forth designate as FtsZup) (Bendezu´ and de Boer, 2008) (Fig-
ure 2C). Surprisingly, however, FtsZup cells remained sensitive
tomecillinam (Figure 2C). Thus, blocking PBP2 function withme-
cillinam is lethal even under conditions where the protein itself
is not essential (Figure 2B). This observation suggested that,
beyond inactivation of the TP activity of PBP2, mecillinam is
also conferring a dominant-negative function to the inactivated
protein. We reasoned that this toxic activity of inhibited PBP2
may stem from the malfunctioning of the Rod system. To test
this hypothesis, we treated cells with both mecillinam and A22ecember 4, 2014 ª2014 Elsevier Inc. 1301
Figure 2. Mecillnam Induces a Lethal Malfunctioning of the Rod System
(A) Shown are the chemical structures of A22 and mecillinam.
(B) Conditional essentiality of PBP2. Cultures of strain HC439/pHC817 [DpbpA Plac::pbpA] harboring either a vector control (pSC101, vector) or a derivative
(pTB63, FtsZup) were serially diluted and spotted on LB agar with either 1 mM IPTG (PBP2 replete) or agar without inducer (PBP2 depletion). Plates were
incubated overnight at 30C and photographed. C. Cultures of strain MG1655 [WT] harboring either pSC101 or pTB63 were serially diluted and spotted on LB
agar as in part B. Agar was supplemented with A22 (10 mg/ml), mecillinam (1 mg/ml), or both drugs as indicated.to simultaneously inactivate the Rod system and the TP domain
of PBP2. Indeed, inactivation of MreB with A22 in FtsZup cells
completely suppressed the toxicity of mecillinam (Figure 2C).
Genetic inactivation of the Rod system was also found to restore
growth to FtsZup cells treated with mecillinam (Figure S1 avail-
able online). The contribution of Rod system malfunction to the
lethal action of mecillinam was also apparent for cells lacking
pTB63. Addition of mecillinam to a culture of wild-type cells led
to a drop in culture OD600 and a loss of viability that was reduced
in severity by cotreatment with A22 (Figures S2A and S2B). The
production of a PBP2 variant with a defective TP active site
[PBP2(S330A)] also killed FtsZup cells (Figure S2C), and this
toxicity could also be suppressed by A22 treatment (Figure S2C).
Thus, the toxicity induced by mecillinam is specific for PBP2 in-
hibition, and not the result of an off-target activity. We conclude
that blocking the TP activity of PBP2 causes the Rod system to
malfunction in a manner that contributes to the lethal activity of
mecillinam.
A Futile Cycle of PG Synthesis and Turnover Is
Responsible for Mecillinam Toxicity
Results from Uehara and Park (2008) previously found that me-
cillinam treatment induced the degradation of newly synthesized
PGwhile A22 blocks synthesis. We suspected that the observed
turnover of nascent PG was key to the lethal mode of action of
mecillinam. We therefore monitored PG synthesis and turnover
using similar procedures to those of Uehara and Park (2008).
Cells were metabolically labeled with [3H]-meso-diaminopimelic
acid (mDAP), an amino acid unique to the peptide moiety of PG1302 Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc.(Figure 3A), following which, PG synthesis can be readily
measured bymonitoring the production of themajor cytoplasmic
precursor UDP-MurNAc-pentapeptide (UDP-MurNAc-pep5) and
the incorporation of label into the PG matrix. [3H]-mDAP labeling
can also be used to quantify PG turnover. Themajor degradation
products of PG are disaccharide fragments liberated by lytic
transglycosylases (LTs) (Fisher and Mobashery, 2014) (Fig-
ure 3A). Rather than hydrolyzing the glycosidic bond, these en-
zymes promote the formation of an anhydro linkage between
the C1 and C6 positions of MurNAc to generate GlcNAc-anhy-
dro-MurNAc-peptides (GlcNAc-anhMurNAc-peptide). These de-
gradation products are normally imported and processed by a
number of enzymes in the cytoplasm for recycling (Fisher and
Mobashery, 2014) (Figure 3A). We therefore used a strain lacking
the amidase AmpD to trap PG turnover products and allow the
quantification of PG degradation without complications of com-
plete recycling (Uehara and Park, 2008) (Figure 3A).
To specifically monitor the effect of drug treatment on PG syn-
thesis and degradation by the Rod system, divisome activity was
blocked during the radiolabeling by expression of the FtsZ
antagonist SulA prior to the addition of antibiotic(s). After 5 min
of growth in the presence of drugs, [3H]-mDAP was added to
the medium and growth was continued for 10 min (1/10th of a
mass doubling). Cells were then harvested and extracted with
hot (90C)water. Soluble compounds (PGprecursors and degra-
dation products) were separated and quantified byHPLC and ra-
diodetection. Material incorporated into the PG matrix was
quantified as radioactive material released from the cell pellet
by lysozyme treatment.
Figure 3. Measurement of PG Synthesis and
Turnover following Mecillinam Treatment
(A) Schematic summarizes the PG synthesis and
recycling pathways. Sugars and peptides are
represented as in Figure 1A. The composition of
the pentapeptide of the cytoplasmic precursors is
L-Ala-gamma-D-Glu-meso-diaminopimelic acid
(mDAP)-D-Ala-D-Ala. UDP-sugars are first made in
the cytoplasm before being transferred to the lipid
carrier undecaprenol-phosphate (Und-P). The final
precursor lipid II is the substrate used by the PBPs
to form PG. As a result of the crosslinking mech-
anism and the activity of carboxypeptidase en-
zymes that remove the terminal D-Ala, the PG layer
consists primarily of glycans with tetrapeptides.
The turnover product circled in red will accumulate
in aDampD strain if nascent PG is degraded during
a pulse labeling experiment. See text for details.
(B) Measurement of PG synthesis and turnover by
the Rod system. Cells of TU278 [DlysA DampD] or
its Dslt derivative (HC419) as indicated producing
SulA to block cell division were pulse labeled with
[3H]-mDAP following treatment with the indicated
drug(s) (10 mg/ml each when added). Soluble me-
tabolites were separated by HPLC and detected
using an in-line radiodetector. The resulting chro-
matograms are shown. Peaks are labeled with
schematics of the corresponding compounds. The
identity of each peak is based on the results shown
in Figure S3. See text for details.In untreated cells, robust incorporation of label into the PGma-
trix was observed (Figure 4). Very little of the newly synthesized
material was degraded as evidenced by the small amount of
labeled anhMurNAc-peptides detected relative to the precursor
pools (Figures 3B, 4, and S3). As reported by Uehara and Park
(2008), we found the effects of A22 treatment differed dramati-
cally from those induced by mecillinam. In cells treated with
A22, incorporation of radiolabel into mature PG was significantly
reduced as expected. This defect was accompanied by in-
creased pools of the PG precursors mDAP and labeled UDP-
MurNAc-pep5 (Figures 3B, 4, and S3), suggestive of a late stageCell 159, 1300–1311, Dblock in the synthesis pathway. Only a
modest increase in anhMurNAc-peptide
accumulation was observed following
A22 treatment, indicating that the drop in
label incorporation into the PG matrix re-
sulted primarily from the inhibition of PG
synthesis. Similarly, in cells treated with
mecillinam, incorporation of label into
PG was also greatly reduced (Figures 3B
and 4). However, as expected from the re-
sults of Uehara and Park (2008), a large
pool of labeled turnover products was de-
tected in mecillinam-treated samples
(Figures 3B and 4). This observation con-
firms the conclusion that, rather than
blocking PG synthesis by the Rod system
like A22,mecillinam induced the degrada-
tion of nascent PG material produced bythe machine. Given that A22 suppressed the toxicity of mecilli-
nam, we wondered if it would also block the apparent futile cycle
of nascent PG synthesis and turnover induced by this beta-lac-
tam. This indeed proved to be the case (Figures 3B and 4),
thus linking the induction of nascent PG turnover with the lethal
mode of action of mecillinam.
PBP inhibition by beta-lactams was previously found to
decrease cellular levels of the final PG precursor, lipid II (Kohl-
rausch and Ho¨ltje, 1991). Based on in vitro PBP assays, it was
recently suggested that the decline in lipid II concentration
may result from the stimulation of glycan strand synthesisecember 4, 2014 ª2014 Elsevier Inc. 1303
Figure 4. Quantification of PG Synthesis
and Turnover following Beta-Lactam Treat-
ment
Cells of TU278 [DlysA DampD] or its Dslt derivative
(HC419) were grown, radiolabeled, and analyzed
as in Figure 3. The amount of UDP-MurNAc-pen-
tapeptide and total anhydromuropeptides pro-
duced were quantified from the area under the
peaks in HPLC chromatograms. Radiolabel incor-
poration into PG was determined by quantifying
the amount of label released from cells by lyso-
zyme. Antibiotic concentrations used were: me-
cillinam (10 mg/ml), A22 (10 mg/ml), cephalexin
(10 mg/ml), and cefsulodin (100 mg/ml). Results are
the average of three independent experiments with
the error bars representing the standard deviation.
The drop in precursor levels between untreated
and mecillinam-treated WT cells is significant (p <
0.005). See text for details.when TP activity is blocked (Banzhaf et al., 2012). A dual mode of
action for beta-lactams was thus proposed where TP inhibition
and substrate depletion act synergistically to promote efficient
bacterial killing (Banzhaf et al., 2012). Our results indicate that
the futile-cycle of PG synthesis and turnover induced by beta-
lactams is likely to be the main driver of the PG precursor deple-
tion observed here and by others (Kohlrausch and Ho¨ltje, 1991;
Uehara and Park, 2008) (Figure 3B and 4). To investigate the
contribution of precursor depletion to the lethal activity of mecil-
linam, we generated strains that overexpress uppS or murA,
which encode enzymes required for the synthesis of the lipid-
carrier Und-P or UDP-MurNAc, respectively (Figure 3A). Impor-
tantly, both strains gained partial resistance to mecillinam
(Figure S2D). Additionally, studies by D’Ari and colleagues (Vine-
lla et al., 1993) showed that high-level overproduction of FtsZ (a 7
3 increase from pZAQ [Begg et al., 1998], as opposed to a 23
increase from pTB63 [Bernhardt and de Boer, 2005]), a condition
where the divisome may more effectively compete with the Rod
system for PG precursors, can partially suppress the lethal ac-
tion of mecillinam. We conclude that mecillinam not only blocks
the TP active site of PBP2, but by doing so, induces a futile cycle
of cell wall synthesis and turnover by the Rod system that con-
tributes to its bactericidal activity, at least in part, by depleting
PG precursor pools.
Futile Cycle Induction Is a Common Property of
Beta-Lactams
We investigated whether inhibiting PBPs other than PBP2 also
stimulates the degradation of nascent PG. Cephalexin is a
beta-lactam that preferentially targets PBP3, the cell division-
specific bPBP (Spratt, 1975). Tomonitor the effect of cephalexin,
we used a modified version of the labeling method described
above. Instead of blocking division with SulA, cell cultures
were treated with A22 to block Rod system activity prior to
[3H]-mDAP addition. This procedure allowed us to focus the
analysis on divisome-mediated PG synthesis. In the absence
of cephalexin, robust incorporation of label into PG by the divi-
some was detected, but with a higher basal level of PG turnover1304 Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc.than when the activity of the Rod systemwas monitored (Figures
4 and S4A). This observation is consistent with previous results
(Uehara and Park, 2008), and most likely reflects the activity of
the cell separation PG hydrolases. Importantly, just as with me-
cillinam, cephalexin treatment led to a dramatic increase in the
degradation of nascent PG (Figures 4 and S4A).
The effect of blocking the TP activity of aPBPs was analyzed
using cefsulodin, a beta-lactam that is specific for PBP1a and
PBP1b (Curtis et al., 1979). Using labeling conditions identical
to those for the mecillinam studies, we also observed a signifi-
cant increase in nascent PG turnover upon cefsulodin treatment
(Figures 4 and S4B). However, this increase was not accompa-
nied by a corresponding drop in label incorporation into the PG
matrix, presumably because PBP2 and other components of
the Rod system remain functional when the TP activity of aPBPs
is blocked. We conclude that the induction of nascent PG degra-
dation is a common property of beta-lactams regardless of the
growth process or class of PBP they target.
Slt Is Responsible for Nascent PG Turnover following
Beta-Lactam Treatment
We reasoned that a genetic selection formutants resistant tome-
cillinammight reveal the cell-wall-degrading enzyme responsible
for the nascent PG turnover induced by beta-lactams. Notably,
selections for mecillinam-resistance were performedmany years
ago by several laboratories (Spratt, 1975; Vinella et al., 1992;
Wachi et al., 1987). This genetic analysis was instrumental in
the initial identification of the genes encoding the Rod system
(mreBCD, pbpA, and rodA). In retrospect, however, these selec-
tionsweremorecomplicated thanoriginally appreciatedbecause
they were carried out in genetic backgroundswith wild-type FtsZ
levels. Thus, basedonour current understanding, theseearlyme-
cillinam-resistance selections were actually demanding mutants
with two changes: (1) those that increase FtsZ levels to render
the Rod system nonessential, and (2) those that generate defects
in the Rod system or other factors in order to alleviate the toxicity
of the futile cycle of PG synthesis and degradation. Consistent
with this view, the classic mecillinam-resistant mutantsmre-129
and mre-678 with lesions in the mreBCD operon (Wachi et al.,
1987) were shown to produce elevated levels of FtsZ (Bendezu´
and de Boer, 2008). Therefore, to simplify the genetic analysis,
we revisited the selections for mecillinam resistance in an FtsZup
genetic background.
MG1655/pTB63 cells were mutagenized with a transposon
and plated on LB agar supplemented with mecillinam. Similar
to prior studies, two classes of resistant mutants were isolated:
those that remained spherical in the absence of mecillinam
and those that regained rod shape when the drug was removed.
As expected, all of the permanently spherical mutants pos-
sessed transposon insertions that mapped to genes encoding
components of the Rod system (data not shown). Mutants in
the second class, however, retained rod-shaped without mecil-
linam and therefore must have a functional Rod system. We
suspected that a subset of these mutants were likely to harbor
insertions in genes important for the degradation of nascent
PG following mecillinam treatment. One such mutant had an
insertion in the slt gene encoding a periplasmic cell-wall-degrad-
ing enzyme called Soluble Lytic Transglycosylase (Slt).
Because LTs cleave glycan strands to generate the
anhMurNAc-peptide products that accumulate following beta-
lactam treatment, we focused on the sltmutant. To test whether
Slt was responsible for beta-lactam-induced turnover of nascent
PG, we performed the radiolabeling assay in a Dslt strain.
Without treatment, the loss of Slt function did not affect net PG
synthesis by either the Rod system or the divisome, but the basal
rate of turnover in each case was reduced (Figure 3B and 4).
Significantly, following mecillinam or cephalexin treatment, the
Dslt strain displayed a dramatically reduced level of nascent
PG turnover relative to the WT strain. Moreover, inactivation of
Slt restored wild-type levels of PG incorporation into the matrix
of mecillinam-treated cells (Figure 4). Slt also appeared to be
important for PG turnover in cefsulodin-treated cells, but unlike
the situation with drugs that inactivate bPBPs, a significant
proportion of the turnover following aPBP inhibition was found
to be Slt independent (Figure 4). Notably, the turnover products
produced upon cefsulodin treatment had a much greater
anhMurNAc-pentapeptide content (25%) than those observed
following mecillinam treatment (4%) (Figures 3B and S4B). This
observation suggests that uncrosslinked, nascent PG with a
relatively high proportion of pentapeptides is formed by the cef-
sulodin-treated cells and that suchmaterial is subject to destruc-
tion by LTs other than Slt. Nevertheless, we conclude that Slt is
likely to be the major enzyme responsible for nascent PG turn-
over following beta-lactam treatment.
Differential Effect of Slt Inactivation on Mecillinam
Sensitivity Depending on FtsZ Levels
Curiously, in contrast to our results, Slt inactivation was previ-
ously found to result in mecillinam hypersensitivity rather than
resistance (Templin et al., 1992). However, in a separate study,
loss of Slt function was shown to increase mecillinam resistance
in a Salmonella typhimuriummutant already partially resistant to
the drug (Costa and Anto´n, 2006). Because the original observa-
tion of mecillinam hypersensitivity for a Dslt mutant was made
with otherwise wild-type cells, and our selection for resistance
was performedwith FtsZup cells, we suspected that the apparentcontradiction was related to cellular FtsZ concentration. Indeed,
we confirmed that for cells lacking Slt and producing normal
levels of FtsZ, the minimal inhibitory concentration (MIC) of me-
cillinam is almost ten times lower (0.04 mg/ml) than that of wild-
type cells (MIC = 0.3 mg/ml). Conversely, as expected from our
genetic analysis, FtsZup cells defective for Slt showed much
higher resistance to mecillinam (MIC > 10 mg/ml) than those
with functional Slt (MIC = 0.3 mg/ml). The change in mecillinam
sensitivity of Dslt cells relative to wild-type as a function of
FtsZ levels was readily visualized on solid medium (Figure 5A).
Importantly, Dslt cells are not generally more sensitive to agents
that target the Rod system; wild-type cells and a strain inacti-
vated for Slt displayed the same A22 sensitivity (Figure S5A).
How can Slt inactivation result in both hypersensitivity and
resistance to mecillinam? To investigate this conundrum, we
compared the effect of mecillinam on the growth and mor-
phology of wild-type and Dslt cells with and without increased
FtsZ production. Microscopic analysis following treatment with
mecillinam for 3 hr revealed that cells lacking Slt undergo a
morphological change at amuch lowermecillinam concentration
than wild-type cells. Moreover, the concentration of drug that
leads to this shape defect was strongly correlated with the con-
centration that induces a growth defect in Dslt cells (Figures 5
and S6). As with the growth phenotype, the morphology of Dslt
cells was only hypersensitive to mecillinam; wild-type and Dslt
cells were found to undergo shape changes at equivalent A22
concentrations (Figure S5). It has been well documented that
the loss of rod shape results in cell division defects and poor
growth unless FtsZ is overproduced (Bendezu´ and de Boer,
2008). We therefore conclude that the mecillinam hypersensitiv-
ity of Dslt cells with normal FtsZ levels results from the morpho-
logical changes and consequent division inhibition induced by
low doses of drug. On the contrary, whenDslt cells have elevated
FtsZ levels, they overcome the adverse effects of the shape
alterations just as mutants with defects in the Rod system are
suppressed by FtsZ overproduction.
Aberrant PG Crosslinking in Dslt Cells Treated with
Mecillinam
The shape change observed for Dslt cells at low doses of me-
cillinam suggests that when uncrosslinked PG produced by
beta-lactam-targeted synthetic complexes is not destroyed by
Slt, it can be misincorporated into the PG matrix to alter
morphology. To investigate this possibility, we analyzed the
composition of purified cell walls (sacculi) isolated from wild-
type or Dslt cells following mecillinam treatment. In wild-type
cells, the total amount of PG isolated following mecillinam treat-
ment was reduced as expected, but the composition of the iso-
lated material, including the relative degree of crosslinking, did
not change dramatically (Figure 6A and Table S1). The muro-
peptide profile of sacculi from untreated Dslt cells was similar
to that observed for wild-type PG. However, following mecilli-
nam treatment, major alterations were observed (Figure 6B
and Table S1). Strikingly, muropeptides with PBP-generated
crosslinks, those linked via the fourth residue of one peptide
and the third residue of the other (a 4-3 crosslink), were almost
completely depleted from mecillinam-treated Dslt sacculi.
This loss was accompanied by a corresponding increase inCell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc. 1305
Figure 5. Effect of Mecillinam on the Growth and Morphology of Cells Defective for Slt
(A) Cells of MG1655 [WT] or HC408 [Dslt] harboring either pSC101 (vector) or pTB63 (FtsZup) were grown overnight, diluted, and spotted on agar containing the
indicated concentration of mecillinam as described for Figure 2B.
(B) The same cells were grown to exponential phase and diluted to an OD600 of 0.025 into LB medium containing the indicated concentration of mecillinam.
Growth was continued for an additional 3 hr and the cells were fixed. The fixed cells were then imaged on agarose pads using DIC optics. Scale bar, 4 microns.muropeptides with an alternative 3-3 (mDAP-mDAP) crosslink
formed by L,D-transpeptidases. Thus, the failure to degrade
uncrosslinked PG produced by beta-lactam-targeted synthetic
machines indeed results in the aberrant incorporation of PG
into the matrix. We conclude that the observed misincorpora-
tion is most likely responsible for the shape defects induced
in Dslt cells treated with low levels of mecillinam. Furthermore,
the accompanying drug hypersensitivity displayed by these
mutants suggests that, in cells with wild-type levels of FtsZ,
the shape changes induced by PG misincorporation are worse
for viability than the consequences of the futile cycle, at least at
low drug concentrations. Accordingly, the growth of Dslt cells
with the vector control is more adversely affected by low doses
of drug than the corresponding WT cells (Figure S6). At higher
drug concentrations, however, functional Slt becomes detri-
mental, presumably due to the increased burden of the futile
cycle as a higher proportion of Rod complexes become tar-
geted (Figure S6).1306 Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc.DISCUSSION
A Common Theme for the Mode of Action of
Bactericidal Drugs
Bactericidal drugs promote cell death while bacteriostatic
agents merely stop bacterial growth. Antibiotics belonging to
both general categories interfere with essential cellular pathways
or enzymes. However, studies of the mode of action of clinically
important drugs in the aminoglycoside and fluoroquinolone clas-
ses provide examples of how bactericidal agents typically do
more than just inhibit their target enzymes. Aminoglycosides
disable the proofreading capacity of the ribosome, causing the
production of mistranslated proteins that are ultimately thought
to cause irreversible membrane damage and death (Davis,
1987). Similarly, fluoroquinolones bind to DNA gyrase and topo-
isomerase IV, leading to the formation of stable drug-enzyme-
DNA complexes that block DNA replication and promote the
formation of double-strand breaks (Hooper, 2001). Thus, rather
Figure 6. Muropeptide Composition of PG following Mecillinam Treatment
Cells of MG1655 [WT] (A) or HC408 [Dslt] (B) were grown to an OD600 of approximately 0.5 and diluted 1:20 into fresh LB medium with or without mecillinam
(10 mg/ml) as indicated. Growth was continued for an additional 3 hr and PG sacculi were prepared from cells of each culture. The purified PG was then digested
with the muramidase mutanolysin and the resulting muropeptides were reduced and analyzed by LC/MS. Total ion count chromatograms are shown with the
chromatograms of the mecillinam-treated samples off-set for clarity. Note that the scales of each chromatogram are not identical. They were scaled to show the
relativemuropeptide composition rather than the total amount ofmaterial. For example, the total peak area in the chromatogram frommecillinam-treatedWT cells
is one third that of the corresponding untreated sample even though an equivalent of twice the volume was injected. Schematics of several major muropeptide
products are shown near their corresponding peaks with the numbers referring to the type of crosslink (4-3 v.s. 3-3). The identities for all labeled peaks and the
quantification of their relative amounts are listed in Table S1. The results were reproducible over two biological replicates of each sample and three technical
replicates for each biological replicate.than simply inhibiting an essential activity, these drugs disrupt
key functions of their target such that the activity of the crippled
enzyme or multicomponent machine becomes toxic and re-
duces viability. Whether beta-lactams elicit a similar toxic mal-
functioning of their target has remained unclear.
The widely accepted view of the mode of action of beta-lac-
tams is that by inhibiting the TP activity of the PBPs, these drugs
simply disrupt the balance between PG synthases and the action
of PG hydrolasesworking to expand the cell wall matrix (Tomasz,
1979). Here, we show that beta-lactams derange the process in
a more direct and insidious manner than this general framework
suggests. Our results indicate that TP inhibition induces the turn-
over of nascent PG material produced by the targeted complex.
In the case of PBP2 targeting bymecillinam, we clearly show that
this turnover contributes significantly to the lethal action of the
drug by inducing the depletion of cellular PG precursor pools
such that even nontargeted PG synthetic complexes are likely
to be adversely affected by beta-lactam treatment. Our findings
thus connect the killing mechanisms of three important and
widely used antibiotics (aminoglycosides, fluoroquinolones,
and beta-lactams); they all stimulate a dominant-negative activ-
ity in their target pathway to induce systemic toxicity. Further-more, all three drug classes typically function against multiple
targets: aminoglycosides target ribosomes made from rRNA en-
coded by several genetic loci per genome (Davis, 1987), fluoro-
quinolones target gyrase and topoisomerase IV (Hooper, 2001),
and beta-lactams typically target several different PBPs in a
given organism (Curtis et al., 1979). It has been discussed previ-
ously that interfering with the activity of multiple cellular targets is
an important property of monotherapies needed to reduce the
incidence of mutational resistance (Silver, 2011). However, the
potential benefit of such therapies inducing a dominant-negative
activity in the affected pathway in addition to hitting multiple tar-
gets has been under appreciated. The combination of these
properties likely enhances antibiotic effectiveness because,
even if one of the targets is mutationally altered to block drug
binding, the sensitivity and lethal malfunctioning of the other tar-
gets will be dominant over the lone resistant allele. Thus, the prin-
ciples learned from this and other studies of the mode of action
of our classic antibacterial therapies indicate that, rather than
searching for simple inhibitors of essential enzymes as has
been common practice, antibiotic discovery efforts should
ideally be seeking new molecules that induce a lethal malfunc-
tioning of multiple cellular targets.Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc. 1307
Figure 7. Role of Slt in Maintaining Coordi-
nation between GT and TP Activity during
PG Biogenesis
Shown is a schematic highlighting the role of Slt in
PG biogenesis. (A) The normal synthetic process
with properly coupled GT and TP activities. The new
glycan strands (brown) are polymerized from lipid-
linked precursors (black zig-zag line) by an enzyme
with GT activity (pink) that may either be the ca-
nonical domain of an aPBP or an as yet unidentified
GT enzyme. The newly polymerized glycans are
rapidly crosslinked into the mature matrix (green) by
anassociatedTPactivity shownhere asabPBP, but
it could also be the TP domain of an aPBP. Other
components of the putative synthetic complex
including cytoskeletal elements were omitted for
simplicity. When the TP active site is damaged or
targeted by a beta-lactam (B), GT activity continues
to produce glycan chains that are no longer cross-
linked into the matrix. In WT cells (C), such strands
are targeted for destruction by Slt. Conversely, in
cells inactivated for Slt (D), the uncrosslinked gly-
cansproducedby thedamaged/targetedmachinery
are not degraded, but are instead aberrantly incor-
porated into thematrix by an alternative crosslinking
enzyme. In cellswithnormal FtsZ levels, the resulting
morphological changes are lethal, leading to beta-
lactam hypersensitivity of Slt-defective cells.A Potential Role for Slt as a Quality Control Enzyme in
PG Biogenesis
In addition to revealing novel features of the beta-lactam killing
mechanism, our findings also shed significant new light on the
process of PG biogenesis. Pulse-labeling studies of PG assem-
bly indicate that nascent PG material is rapidly crosslinked into
the mature matrix (Burman and Park, 1983; Glauner and Ho¨ltje,
1990), indicating a tight coupling between GT and TP activities.
Such an orderly insertionmechanism is likely critical for themain-
tenance of proper cell shape and integrity. Here, we show that
the inhibition of TP activity by beta-lactams functions to uncouple
glycan polymerization from crosslinking, leading to the gene-
ration of uncrosslinked glycan strands (Figure 7). Our results
indicate that this nascent material is rapidly degraded in an Slt-
dependent manner, setting up a futile cycle of synthesis and
degradation (Figure 7). Mutants defective for other PG cleaving
enzymes were not isolated in selections for mecillinam resis-
tance. Additionally, nascent PG turnover was largely eliminated
in the absence of Slt. We therefore conclude that Slt is likely to
be directly responsible for destroying the uncrosslinked material
produced by the beta-lactam-targeted synthetic machinery.
How Slt is activated to degrade uncrosslinked PG is not
known. Importantly, affinity chromatography studies identified
a potential interaction of Slt with PBPs 1b, 2, and 3 in E. coli
(von Rechenberg et al., 1996; Romeis and Ho¨ltje, 1994), sug-
gesting that the turnover we observemay be stimulated by asso-
ciation with the beta-lactam-targeted synthases. Additionally,
Slt is known to have a doughnut-like structure with the active
site oriented toward a central hole wide enough to accommo-
date only a single uncrosslinked glycan chain (Thunnissen
et al., 1994). Thus, the enzymemay have a strong substrate pref-
erence for uncrosslinked glycan chains, a possibility that is sup-1308 Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc.ported by the observation that pretreatment of purified cell wall
sacculi with an endopeptidase stimulates the release of soluble
material by Slt (Romeis and Ho¨ltje, 1994). This apparent sub-
strate preference may contribute to its role in the futile cycle in
addition to, or independent of, an interaction with the PBPs.
Notably, Slt functions primarily as an exoglycosidase (Beachey
et al., 1981) with some detectable endoglycosidase activity
(Lee et al., 2013). Although it has been argued that Slt degrades
glycan chains from an anhydro-MurNAc end (van Asselt et al.,
1999), the structural data are also consistent with Slt processing
glycan strands from the nonreducing end as has been demon-
strated biochemically. We therefore envision that Slt may either
recognize an existing, free nonreducing end of an uncrosslinked
glycan, or, in the case of partially crosslinked material, it could
create such an end with its weak endoglycosidase activity, fol-
lowed by the degradation of the remaining uncrosslinked glycan
chain.
The physiological role of Slt has remainedmysterious for some
time. It has been implicated in the turnover of mature cell wall
material and cell separation (Heidrich et al., 2002; Kraft et al.,
1999). However, these functions have been ascribed to Slt based
on the phenotypes of mutants lacking multiple PG processing
enzymes, suggesting that they represent secondary activities.
Clues to the likely primary physiological function of Slt were pro-
vided by our analysis of the response of Dslt cells to mecillinam
treatment. In the absence of Slt, PG produced bymecillinam-tar-
geted synthetic complexes was found to be aberrantly incorpo-
rated into the PG matrix via the formation of alternative (3-3)
crosslinks by non-PBP transpeptidases. Additionally, the mor-
phology of Dslt cells was dramatically altered following exposure
to low doses of mecillinam, while the same treatment had little
effect on the shape of wild-type cells. Because these drug
concentrations are well below the IC50 for PBP2 (Curtis et al.,
1979), only a fraction of the cellular PBP2 pool is predicted to
be inhibited in cells treated with this level of mecillinam. Thus,
the morphological changes displayed by Dslt cells exposed
to low concentrations of mecillinam are unlikely to be due to
general inhibition the Rod system. Instead, we conclude that
misincorporation of uncrosslinked PG produced by mecillinam-
targeted machines is likely to be responsible for the shape
change of the mutant, most likely because the aberrant material
creates a local defect in the matrix that interferes with the proper
assembly or remodeling of PG by other (untargeted) machines.
By extension, we infer that a major function of Slt is to prevent
the stable accumulation of uncrosslinked glycan strands so
that they are not aberrantly crosslinked into the mature matrix.
Such an activity is consistent with a novel ‘‘quality control’’ or
‘‘repair’’ function that helps maintain cell shape and integrity.
In our experimental system, low drug concentrationmost likely
serves to mimic environmental damage to the synthetic machin-
ery or other natural conditions resulting in the uncoupling of GT
and TP activities. For example, uncrosslinked glycan strands
might accumulate if synthetic complexes enter an area of the
PG matrix with few peptides available to accept crosslinks. In
these cases, we envision that glycan chain degradation by Slt
might facilitate the exchange of a damaged TP for a functional
one, and/or allow the release of stalled complexes tethered to
a partially crosslinked glycan strand so that they can restart syn-
thesis at other locations. In support of the latter possibility,
recent studies indicate that bPBPs are likely to be dynamically
associated with the synthetic machinery (Lee et al., 2014).
An additional phenotype consistent with a quality control func-
tion for Slt is the rapid lysis displayed by Dslt cells treated with
cephalexin (Templin et al., 1992). PBP3 inactivation normally re-
sults in a division block and the formation of filamentous cells
that lyse many mass doublings after cephalexin addition (Spratt,
1975). However, cells defective for Slt lyse rapidly following ceph-
alexin treatment (Templin et al., 1992). Rapid lysis under these
conditions is known to require the activity of the cell separation
amidases (Heidrich et al., 2001). By analogy with mecillinam-
treated cells, addition of cephalexin to Dslt cells likely results in
the production of stable uncrosslinked glycan strands that can
be misincorporated by alternative crosslinking enzymes. Lysis
may result because this misincorporated material mimics pro-
ductive PG synthesis by the divisome such that the cell separa-
tion enzymes are activated to process the malformed material
resulting in a localized breach in the PG. Thus, in addition to
shape maintenance, the proposed quality control function of Slt
may also enforce the coupling of GT and TP activities to prevent
the misactivation of PG hydrolases by damaged PG synthases.
Taking this line of reasoning a step further, it is interesting to
speculate that it may be the failure of Slt to process certain types
of glycan strands (e.g., thosewith high pentapeptide content) that
underlies the ability of some beta-lactam drugs to induce rapid
cell lysis via the misactivation of autolytic PG hydrolases.
Slt, Beta-Lactamase Induction, and Potential
Combination Therapies
Many gram-negative bacteria encode a beta-lactamase (AmpC)
produced in response to beta-lactam treatment (Fisher and Mo-bashery, 2014). In some organisms, expression of the ampC
gene is controlled by the transcriptional regulator AmpR (Jacobs
et al., 1997). Mutants defective for the AmpD amidase involved in
cell wall recycling were found to overexpress ampC even in the
absence of beta-lactams (Jacobs et al., 1994). This finding along
with supporting in vitro transcription experiments has led to a
model in which beta-lactam treatment leads to the accumulation
of anhMurNAc-peptide turnover products in the cytoplasm that
serve as a signal for ampC induction (Fisher and Mobashery,
2014; Jacobs et al., 1997). It has been widely assumed that these
recycling intermediates increase in concentration because beta-
lactams induce general cell wall damage. Here, we have shown
that targeting PG synthetic machines with beta-lactams causes
nascent PG to be degraded by Slt, generating high levels of
anhMurNAc-peptides. Thus, rather than generic insults to the PG
matrix, the ampR-ampC regulatory system is perfectly tuned to
detect the futile cycle of PG synthesis and degradation induced
upon TP inhibition. Importantly, based on the critical role
observed for Slt in ampC induction (Kraft et al., 1999) and the hy-
persensitivity of Slt-defective mutants to beta-lactams (Templin
et al., 1992), it has been proposed that Slt inhibitorsmay be useful
in combination therapieswith beta-lactams (Kraft et al., 1999).Our
results provide a mechanistic picture of what such combinations
would likely accomplish. The downside of blocking Slt activity
simultaneously with beta-lactam treatment would be loss of the
toxic effects of the futile cycle and subsequent precursor deple-
tion. However, what would be gained is an alternative malfunction
of PG biogenesis caused by the accumulation of uncrosslinked
glycan strands that can cause lysis or lethal shape changes as
described above. Thus, inhibiting Slt function should indeed be
an effective way to stymie beta-lactamase induction systems in
gram-negative pathogens while still allowing beta-lactams to
derange the PG biogenesis machinery to promote cell death.CONCLUSION
Beta-lactams are arguably one of themost important therapeutic
classes in the history of medicine. In this report, we present data
that changes the view of how these drugs work. They are not
simple inhibitors of cell wall synthesis as is commonly believed.
Instead, they derange the activity of the PG biogenesis machin-
ery to induce a futile cycle of PG synthesis and degradation that
depletes cellular resources. While investigating the nature of the
futile cycle, we uncovered what appears to be a new role for PG-
cleaving enzymes as quality control factors that intervene when
problems arise during PG synthesis. Overall, these new insights
provide a mechanistic foundation that will not only help us better
understand the process of cell wall biogenesis, but also howbest
to interfere with it for the development of novel antibacterial
treatments.EXPERIMENTAL PROCEDURES
Media, Bacterial Strains, Plasmids, and Culture Conditions
Cells were grown in LB or minimal M9medium supplemented with 0.2% casa-
mino acids and carbon source (0.4% glycerol or 0.2% maltose) as indicated.
The bacterial strains and plasmids used in this study are listed in Tables S2
and S3, respectively.Cell 159, 1300–1311, December 4, 2014 ª2014 Elsevier Inc. 1309
Measurement of the Turnover of Newly Synthesized PG
The effect of beta-lactams and A22 on the turnover of nascent PG was moni-
tored by using DlysA DampD strains essentially as described previously (Ue-
hara and Park, 2008). Cells of the relevant strains were grown overnight in
M9-glycerol medium with 0.2% casamino acids. The resulting cultures were
then diluted to an OD600 of 0.04 in the same medium and grown to an OD600
between 0.3–0.4 at 30C. For experiments measuring PG synthesis and turn-
over by the Rod complex, sulA expression was induced from a chromosomally
integrated plasmid (pHC739) for 30 min before drug treatment. The cultures
were then treated with the indicated beta-lactams and/or A22 for 5 min after
adjusting the culture OD600 to 0.3. Following drug treatment, [
3H]-mDAP
(1 mCi) was added to 1 ml of each culture for 10 min (1/10 of the doubling
time) to label the newly synthesized PG and its turnover products. After the la-
beling, cells were pelleted, resuspended in 0.7 ml water, and heated at 90C
for 30 min to extract water-soluble compounds. After the hot water extraction,
insoluble material was pelleted by ultracentrifugation. The resulting superna-
tant was then removed, lyophilized, and resuspended in 0.1% formic acid
for HPLC analysis. To determine [3H]-mDAP incorporated into the PG matrix,
the pellet fraction was washed and treated with lysozyme. The suspensions
were incubated overnight at 37C. Insoluble material was then pelleted by
centrifugation, and the resulting supernatant was subjected to scintillation
counting. Similar procedures were used for measuring PG synthesis and turn-
over by the divisome following cephalexin treatment except that Rod system
activity was suppressed by treating the cultures with A22. See Supplemental
Information for a detailed protocol.
Muropeptide Analysis of PG Sacculi Isolated from
Drug-Treated Cells
Cultures of MG1655 and its Dslt derivative, HC408, were diluted in 1 l of LB or
LB containing 10 mg/ml mecillinam to OD600 of 0.025 and incubated at 30
C for
3 hr with shaking. The OD600 of each culture reached approximately 0.6 at the
end of the growth period. PGwas then purified from each culture and analyzed
by LC/MS as described in Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2014.11.017.
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